Efficacy and safety of durvalumab plus tremelimumab versus standard chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis of phase III randomized controlled trials. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback